DEXCOM INC
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
SYSTEMS AND METHODS FOR COMMUNICATION WITH ANALYTE SENSOR ELECTRONICS
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets
DexCom’s latest valuation work now centers on a fair value anchor of US$81.64, slightly below the prior US$83.54 level and closer to the current range of Street targets. Many firms have trimmed price targets after recent Analyst/Investor Day updates, reflecting a balance between confidence in execution and a more cautious stance on longer term growth and valuation assumptions. As you read on, you will see how these shifting targets, together with fresh guidance and product news, shape the...
Dexcom: A Medical Platform Play Gaining From AI, Not Disrupted By It
Dexcom (DXCM) uses AI to boost margins and innovate CGM with Stelo for prediabetes.
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo
The wearables in pharma & biotech market is forecasted to grow from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%. This rapid growth is fueled by advances in biosensor technology, miniaturization, and digitization, supported by strong internet connectivity worldwide. Programs like "All of Us" and RPM adoption are boosting wearables' role in research and healthcare. CGMs lead product segments due to robust clinical backing, while pharma and biotech companies were top en
Congressional Trades in $DXCM
Insider Trades (Form 4)
SAYER KEVIN R
Key People
SAYER KEVIN R
Executive Chair
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro